Therapeutic area intelligence for Combination Analgesic with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Sun Pharma →

Assets

FDA →

Recent signals(2)

RegulatoryJune 26, 2026

FDA Accepts Supplement Application for SYNALGOS-DC by Sun Pharma

The FDA has accepted a supplemental application for SYNALGOS-DC, a combination analgesic.

RegulatoryJune 26, 2026

FDA Approves Supplemental NDA for SYNALGOS-DC by Sun Pharma

The FDA has approved a supplemental NDA for SYNALGOS-DC, which contains aspirin, caffeine, and dihydrocodeine bitartrate.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.